about
What do oncologists need to know about biosimilar products?Hepatotoxicity of targeted therapy for cancer.PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingDrug development for hepatocellular carcinoma: knowing the past helps to understand the futureAssessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI gradeA small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.Hong Kong consensus recommendations on the management of hepatocellular carcinoma.Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeImpact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionNovel systemic therapeutic for nasopharyngeal carcinoma.Targeted therapy of hepatocellular carcinoma: present and future.Management of hepatocellular carcinoma: beyond sorafenib.Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.An update on the safety and efficacy of regorafenib in the treatment of solid cancers.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.Lymphedema and quality of life in Chinese women after treatment for breast cancer.Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma.Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma.Misleading chest radiography in a patient with SARS.Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenibEmbedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker DiscoveryThe association of liver function and quality of life of patients with liver cancerNeed of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trialsIntra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspectivePARP inhibition in BRCA-mutated breast and ovarian cancersSelecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right populationEconomic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong KongPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialGenome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma
P50
Q28071687-C0DCCF6B-BB6A-4E8D-8417-17E3CC1737B1Q30250288-B7E30C28-3D66-4CD3-B62A-1AA4A70C2AFCQ33395400-287A652B-F89C-41B7-9260-879704FB3F9AQ34382581-B9980947-22B2-4C55-A395-FEDF8391ECA4Q34458068-23901C6A-4CC7-412F-A31D-8BD0A88E7A73Q35065472-9E830271-C3A0-4422-B92F-A5F0674B1F15Q35251019-5F23A368-2277-4361-8B3A-1FD19AAA57FEQ35631295-B81E3E1C-9D54-40FF-B99E-3BB17639C996Q37174913-48DC3AB5-4FDA-4648-AAC8-B39E99C040AAQ37655084-9E00C573-F3E8-4A2B-88E2-CB74EF68AAF3Q37655092-9069A620-C1B0-4C10-8F43-F446A65918D8Q37982126-442AF019-9BDC-444F-A9AB-86934D1CD666Q37988604-6A965F94-2E71-4C13-A6B0-4AAD2E995F0CQ37995523-94FFC9EA-3B3A-44D0-829C-F6D4C59017D4Q38152608-7F96AB20-F301-4DEA-9CA8-3D2E61E2CDC5Q38201707-DEB3C062-F7E7-454B-ACB7-30747F65F30EQ38260324-B5267FDC-9542-45D1-A8F7-9722020AC2B4Q38375159-A8904602-7D67-44D4-A7ED-587C57D053D3Q38778021-5F0EEE67-3853-4437-813E-40FB432A5A98Q38905340-0DAFDF88-8037-4583-9139-C4D7407C580AQ39405116-C854F2E7-3CB7-419A-9658-9867E0CFECC5Q40099772-F13296A6-78EA-4C02-8BB7-0201C01C5939Q41344288-03F8976D-E840-4A23-AA1F-F89A660D295BQ43910551-2C178DF0-4AE4-4133-BA29-023CB2102AF6Q44626437-C07C17DD-340A-41A9-8987-093139636EDEQ45871510-8C8254F7-F521-42A8-ADFF-926EEA9A4F5AQ47633619-7C50878B-D11F-4058-BC1A-B7B2FE8D9339Q53162619-D03C2F2F-12A1-4F1C-9272-FB4A4ADCB59EQ54234543-E335D6EC-6EA3-459F-8353-A60CC874C900Q58699475-678ADB2C-BD36-4BDA-B918-45A0C8FD33DFQ60920689-1C61EE68-AF66-4DA5-A447-916BB929D452Q64069871-C298366D-1FF2-4572-B490-C1A2207C9D49Q82738184-89E45432-D940-4D1E-9210-2F0AFF51518BQ83958478-18015EE0-5B3A-4019-A2CA-5E84E623A6AAQ84591315-31577385-70C0-4CB4-BA3E-91DC419F0028Q86150347-A2B0275B-490E-40F0-8CB4-55617621F5F1Q87054562-2D5D3669-EF3C-4047-A006-870265CCBC1DQ87361303-FE5B4E66-7FAC-49A3-AC7C-FD2D3308F88AQ89012806-7F1FC638-CE17-47D9-8142-1962854F0B88Q91339881-477768F3-5269-46A4-95DC-3004A285E83B
P50
description
researcher ORCID ID = 0000-0001-8998-5480
@en
name
Stephen L Chan
@ast
Stephen L Chan
@en
Stephen L Chan
@nl
type
label
Stephen L Chan
@ast
Stephen L Chan
@en
Stephen L Chan
@nl
prefLabel
Stephen L Chan
@ast
Stephen L Chan
@en
Stephen L Chan
@nl
P31
P496
0000-0001-8998-5480